Paul G. Richardson

TL;DR: Isatuximab and daratumumab possess similarities and differences in their mechanisms of action, likely imparted by their binding to distinct, nonoverlapping epitopes on the CD38 molecule as discussed by the authors .

TL;DR: It is concluded that frontline ASCT remains a standard of care for a substantial proportion of patients; however, delayed/salvage ASCT is increasingly being used in the context of highly active frontline regimens based on novel agents and the ongoing personalization of myeloma treatment.

TL;DR: NPI-0052, like bortezomib, blocks MM cell growth induced by both adhesion to bone marrow stromal cells (BMSCs) and related cytokine secretion, thereby depriving MM cells of the growth and survival advantage conferred by the BM microenvironment, and NPI-052-triggers MM cells apoptosis despite the presence of interleukin-6 or insulin-like growth factor-1 (IGF-1), two major growth

TL;DR: Overall, MRZ was well tolerated, did not add to the incidence or severity of Pomalidomide/Lo-DEX AEs and the regimen may have fewer hematological and infectious AEs compared to that observed with POM/Lo -DEX.

TL;DR: Over 52-week follow-up, the risk of hepatotoxicity was similar in HIV-negative opioid injectors receiving brief and prolonged treatment with BUP/NX, and data suggest that most hepatotoxic events observed during treatmentWith BUP-NX are due to other factors.